Brandon Aden

A recent study in Health Affairs by CHERISH Research Affiliate Dr. Yuhua Bao and CHERISH investigators Dr. Zachary Meisel and Dr. Bruce Schackman examined the impact of prescription drug monitoring program policies on high-risk opioid prescriptions. Prescription drug monitoring programs (PDMPs) are statewide databases of controlled substances dispensed at retail pharmacies. Currently, all states and Washington D.C. except Missouri […]

In the opening plenary panel of the CHERISH (Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV) conference on evidence-based policy and practice are (l to r) Daniel Polsky, PhD, moderator and Executive Director of the University of Pennsylvania’s Leonard Davis Institute of Health Economics (LDI); Tom McLellan, PhD, Chairman of the Board and […]

The Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV (CHERISH) was profiled at the Liver Meeting® 2016 in Boston, MA. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors that informs substance use disorder treatment policy and HCV and […]

There are more deaths in the US from opioids than from any other unintentional injury–one person died every 30 minutes from an opioid analgesic overdose in the US in 2014. The experience of living with opioid use is harmful both for the opioid user and for his or her spouse. A recent study published in the journal Addiction quantified […]

The high costs of treating the more than 7 million people with a substance use disorder may be daunting to public and private payers. The costs of not treating them may be even higher, especially if you consider the costs of failing to screen for and treat HIV and hepatitis C in this population. Sorting […]